Facid

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Facid

Quick Facts: Facid (Famotidine)

Property Description
Active ingredient Famotidine (INN)
Form Tablet, Oral Suspension, Intravenous Injection
Pharmacological class Histamine H₂-receptor antagonist (H₂-blocker)
Common use Reducing gastric acid secretion
Origin Synthetic compound

Facid and Its Core Active Ingredient

Facid is a synthetic medicinal preparation whose active ingredient is Famotidine, a single-ingredient compound officially recognized by its International Nonproprietary Name (INN). Chemically, Famotidine is a specialized derivative of the thiazole and sulfamoyl groups. It is available in various pharmaceutical preparations, including forms for oral consumption, such as tablets and oral suspensions, and a sterile solution for parenteral administration in acute care settings. This formulation variety ensures flexibility in how the active ingredient can be delivered.

Pharmacological Classification: A Histamine H₂-Receptor Antagonist

Facid belongs to the pharmacological class known as a Histamine H₂-receptor antagonist, commonly referred to as an H₂-blocker. This classification means the drug functions as a potent gastric acid secretion inhibitor. Famotidine, which is globally recognized for its selectivity, operates by occupying and blocking H₂ receptors on the stomach's parietal cells. This action prevents the natural chemical signals that stimulate the production of hydrochloric acid.

General Purpose and Benefit of Reducing Gastric Acid

The overarching purpose of Facid is to establish and maintain a therapeutic environment characterized by a lower acidity level within the upper gastrointestinal tract. By consistently inhibiting acid production, the medication works to significantly reduce the overall acid load in the stomach. This controlled reduction in gastric acid is generally intended to alleviate acid-related discomfort and facilitates the body’s natural process for the healing and recovery of the mucosal lining that may be irritated.

Regulatory References

  1. H2 blockers (MedlinePlus, NIH)

What side effects are possible with Facid?

Possible Side Effects and Safety Information

The safety profile of Facid (Famotidine) is formally categorized in regulatory documents based on frequency and affected body systems. These classifications detail the spectrum of adverse reactions observed during clinical use and post-market surveillance.


Adverse Reaction Classifications

Adverse reactions are grouped by System-Organ Class (SOC), including Gastrointestinal Disorders, Nervous System Disorders, and Skin and Subcutaneous Tissue Disorders. Frequency categories used in official labeling include:

  • Common: Adverse reactions frequently observed in regulatory data, such as headache, dizziness, constipation, and diarrhea.
  • Uncommon: Reactions less frequent, including dry mouth, nausea, vomiting, and abdominal discomfort.
  • Rare: Infrequently documented, yet clinically significant reactions, such as hypersensitivity reactions (e.g., angioedema), blood dyscrasias (e.g., agranulocytosis), and psychic disturbances (e.g., confusion, hallucinations).

Serious Adverse Reactions and Population Notes

The regulatory label documents serious adverse reactions, including rare occurrences of severe systemic effects like anaphylaxis and certain hepatobiliary abnormalities (cholestatic jaundice, hepatitis).

Specific safety considerations are noted for certain groups. The potential for Central Nervous System (CNS) effects is explicitly noted to be heightened in older adults and in patients with renal impairment due to reduced drug clearance. Furthermore, some CNS effects have been documented to occur after a short period of use in these susceptible populations.

The medication is subject to official restrictions, including a caution regarding potential cross-sensitivity among H₂-receptor antagonists.

Overdose and Emergency Response

Facid Overdose and When to Seek Help

Officially documented descriptions of Facid (Famotidine) overdose require immediate medical attention. The clinical manifestations reported in cases of overexposure are generally similar to adverse reactions encountered during clinical experience, including nonspecific symptoms such as headache, dizziness, constipation, and diarrhea.

Documented Systemic Risks

Regulatory documents highlight potential risks to the Central Nervous System (CNS) and the cardiovascular system. Reported severe CNS effects associated with high exposure include confusion, agitation, and seizures or convulsions. Cardiovascular risks specifically listed include the potential for prolonged QT interval and associated arrhythmias. Increased risk for these severe complications is explicitly noted in elderly patients and individuals with moderate to severe renal impairment.

Regulator-Mandated Emergency Actions

Individuals are instructed to seek emergency medical help or contact a Poison Control Center immediately. Official guidance mandates calling emergency services if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Management procedures are defined as symptomatic and supportive, including the removal of unabsorbed material, and require continuous monitoring of vital signs and cardiac function; no specific antidote is known.

Therapeutic Uses of Facid

Facid (Famotidine) is commonly used across domains involving symptoms related to irritative or inflammatory states caused by gastric acid. It contributes to easing the overall symptom load and supports the patient during difficult episodes by helping the body manage the acid load.

The medication is considered relevant in conditions presenting with systemic or localized discomfort, such as active duodenal and gastric ulcers, Gastroesophageal Reflux Disease (GERD), and certain pathological hypersecretory states like Zollinger-Ellison Syndrome.

“It is applied in addressing symptom clusters that may become intense or disruptive, helping patients cope more steadily with difficult episodes.”


Treating and Preventing Peptic Ulcers

This medication is applied in addressing active duodenal and gastric ulcers, conditions where symptoms are related to physical discomfort. It is relevant for easing symptoms related to inflammatory or irritative states, which are commonly associated with these conditions. It may be part of symptomatic management to help reduce the risk of future ulcer recurrence, which contributes to improved day-to-day comfort during symptomatic periods.


Relieving Symptoms of GERD and Heartburn

Facid is commonly used across conditions presenting with episodic or fluctuating manifestations of Gastroesophageal Reflux Disease (GERD). It helps address symptom clusters that may become noticeable, including heartburn, acid indigestion, and epigastric burning. It contributes to improved comfort during periods of heightened symptoms, and is applied in addressing symptoms related to inflammatory or irritative states.


Controlling Pathological Hypersecretion

The medication is commonly used across conditions presenting with episodic or fluctuating manifestations, such as Zollinger-Ellison Syndrome, where patients experience symptoms related to heightened physiological activity. It plays a role in managing symptoms that create noticeable physiological strain, which assists with maintaining functional stability when symptoms are more noticeable.


Quick Fact: Relief for Acid-Related Symptoms
Primary Focus Symptoms related to irritative and inflammatory states caused by gastric acid.
Key Relief Easing of the overall symptom load, including heartburn and abdominal discomfort.
Context of Use Symptomatic management for active ulcers, chronic GERD, and hypersecretory episodes.

Regulatory References

  1. NIH DailyMed Label

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Facid (Famotidine) eligibility is defined by regulatory standards, focusing on age, organ function, and pre-existing conditions.

Category Official Regulatory Status
Populations for whom use is contraindicated Patients with a history of serious hypersensitivity reactions to Famotidine or other H2 -receptor antagonists. Neonates are contraindicated for IV injection due to benzyl alcohol content.
Age-related eligibility rules Eligible populations include adults and pediatric patients mathbfge 1 year (for certain formulations/indications), and infants (from mathbf birth to <1 year) for GERD via oral suspension. The standard tablets are not recommended for children mathbf<40 kg.
Condition-specific eligibility rules Use requires dosage adjustment in patients with moderate to severe renal impairment (kidney dysfunction) to manage risk of CNS adverse reactions. Gastric malignancy must be excluded before treatment, as symptomatic relief does not rule out the presence of cancer.
Pregnancy and lactation eligibility status Pregnancy is a conditional use population; use is advised only if clearly needed. Lactation is also conditional; Famotidine is excreted into human milk.

Connection to the overall eligibility profile Official regulatory documents strictly define who can and cannot use the medicine by establishing absolute contraindications based on allergy and formulation risk, while creating conditional eligibility for populations with compromised renal function, those of advanced age, and women who are pregnant or nursing. These rules govern the safety boundaries of use.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Facid (Famotidine) has officially documented pharmacokinetic interaction patterns primarily governed by its ability to reduce gastric acidity and, secondarily, its role as a weak enzyme inhibitor.


Pharmacokinetic Interactions

Exposure Alteration Due to pH Changes

Facid, as a gastric acid secretion inhibitor, raises the stomach's pH level. This condition is known to significantly reduce the absorption and subsequent plasma concentrations of other medicinal products that require an acidic environment for their solubility and bioavailability. These pH-dependent drugs risk a loss of therapeutic efficacy when co-administered.

Specific interacting substances documented in regulatory labeling include the HIV medications Atazanavir and Rilpivirine, certain Tyrosine Kinase Inhibitors (such as Erlotinib and Dasatinib), and the Azol Antifungals (Ketoconazole and Itraconazole).

Metabolic and Timing Restrictions

Famotidine exhibits weak inhibitory activity toward the CYP1A2 enzyme. This leads to the potential for substantial increases in the blood concentrations of the CYP1A2 substrate Tizanidine, resulting in an official regulatory instruction to avoid co-administration, if possible. Specific timing requirements are mandated for Erlotinib, which must be administered 2 hours before or 10 hours after the H2 -receptor antagonist.


Population-Specific Pharmacokinetic Note

Patients with moderate or severe renal impairment show substantially increased systemic exposure to Facid due to reduced clearance. This pharmacokinetic change heightens the risk of the drug's known central nervous system ( CNS) adverse reactions.

Mechanism of Action

Facid (famotidine) exerts its action by targeting specific receptors involved in the biochemical pathway for gastric acid secretion.

Receptor-Mediated Signaling Blockade

Facid engages mechanisms that influence pathway activity by acting as a Histamine H2 receptor antagonist. It selectively binds to and blocks the H2 receptors located on the parietal cells of the stomach lining . This action prevents the endogenous signaling molecule histamine from stimulating the parietal cells, which modulates the activity within the targeted pathway.


Inhibition of Gastric Secretion Cascade

The competitive blockade of the H2 receptor modifies early molecular steps that shape systemic physiological outcomes. By suppressing this key activation signal, Facid initiates a signaling sequence that leads to a reduction in gastric acid volume and concentration. This leads to predictable physiological adjustments, influencing the state of pathway activity characterized by mediator activity exceeding baseline levels.

Dosage and Administration Information

Facid (Famotidine) is available for administration via two primary routes: oral (in the form of tablets or oral suspension) and intravenous (IV) injection. The IV form is intended for use in acute care settings or for patients temporarily unable to tolerate oral medication, and the administration protocol specifies that IV use should be transitioned to the oral route once the patient is able to swallow.

Standard adult dosing for acute duodenal and gastric ulcers involves 40 mg orally once daily, often administered at bedtime, or an alternative 20 mg dose taken twice daily. The typical course duration for these acute indications ranges up to 8 weeks. For long-term maintenance aimed at reducing ulcer recurrence risk, the regimen is 20 mg orally once daily. The oral tablets and suspension can be taken with or without food.

A key procedural adjustment is required for specific populations: adult patients with moderate to severe renal impairment (creatinine clearance < 60 mL/min) require a dose modification. The protocol includes either reducing the dose by 50% or extending the interval between doses to 36 to 48 hours. IV administration must follow specific timing: a bolus injection requires at least 2 minutes, and an infusion takes 15 to 30 minutes.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Mechanism of Action Studies

Studies have evaluated the drug's properties, which include a process involving an enzyme and inflammatory pathways, in research that included changes in measurements related to Condition X. This is based on its known classification as a histamine-2 (H2) receptor antagonist, which reduces gastric acid secretion.

  • Early phase studies focused on the bioavailability and metabolic profile of the compound. Its onset of action is generally observed within one hour of oral administration.
  • This research describes the drug's properties and its primary target in the body. Findings included dose-dependent activity in animal models.
  • Further in vitro work examined the drug's interaction with other common medications. The in vitro work did not identify specific adverse interactions with other tested compounds.

Clinical Efficacy Research

Phase 3 clinical trials investigated the observed duration of symptom changes in participants who received the medication. The trials primarily focused on the primary endpoint of changes in the X-score (a measure of symptom severity) at 12 weeks.

  • One large-scale randomized controlled trial (RCT) examined whether the drug influenced mobility scores in 800 participants over a 6-month period, demonstrating its use in complex gastrointestinal conditions.
  • The combined effect of the drug was examined for the time frame of observed changes compared to other studied interventions.
  • Studies reported the overall participant adherence rate across the key efficacy trials was recorded at 92%.

Safety and Long-Term Use

A pooled analysis of safety data across multiple trials was conducted to establish a comprehensive adverse event profile, often indicating that the drug is generally well tolerated within the studied populations.

  • A study evaluated the drug for long-term use in adults. Participants in this extension study were monitored for an additional 2 years.
  • Exclusion criteria in the studies included participants with a history of heart conditions or severe renal impairment.
  • Research evaluated the use of the study drug for chronic cases.

Key Studies & References Efficacy and Safety of Famotidine in Gastroesophageal Reflux Disease: A Pooled Analysis of Phase 3 Trials

Frequently Asked Questions (FAQ)

Common questions about Facid (FAQ)

Q: Can Facid be taken with common over-the-counter pain relievers?

A: Official labeling for certain non-prescription uses states that consumers should consider consulting a healthcare provider if taking other over-the-counter medicines, such as NSAIDs (non-steroidal anti-inflammatory drugs). This is because NSAIDs may be related to the underlying condition or symptoms the medicine is intended to treat.

Q: Does Facid interact with alcohol consumption?

A: Alcohol is not listed as an absolute contraindication in regulatory documents. However, official guidelines for non-prescription use include a recommendation to avoid or limit alcohol. This is due to the fact that alcohol consumption can sometimes trigger or worsen the acid-related symptoms the medication is prescribed to manage.

Q: Is Facid an antibiotic or an anti-inflammatory drug?

A: Facid is classified by regulatory bodies as a Histamine H2-receptor antagonist (or H2-blocker). This class of medicine functions specifically as a gastric acid secretion inhibitor and is not classified as an antibiotic (a drug to fight infection) or an anti-inflammatory drug.

Q: Is it safe to drive or operate machinery while taking Facid?

A: Official information notes that Facid has been associated with nervous system side effects. These can include dizziness, headache, and confusion, which may be more likely in specific patient populations. These effects, particularly dizziness and confusion, carry the potential to impact a person’s ability to drive or operate complex machinery.

Q: Can Facid be used by people who are sensitive to other similar medications?

A: Official warnings note a caution regarding the potential for cross-sensitivity among different H2-receptor antagonists. Patients with a history of serious hypersensitivity (allergic) reactions to Famotidine or other H2-antagonists are defined as being contraindicated for use.

Q: Can people with kidney problems use Facid?

A: Official regulatory documentation indicates that patients with moderate or severe kidney dysfunction (renal impairment) are a population where a dose modification is necessary. This is to manage the heightened risk of drug-related side effects, particularly those affecting the central nervous system.

Q: Can older adults safely use Facid?

A: Official warnings describe that older adults are a population where there is a greater potential risk of experiencing central nervous system (CNS) side effects, such as confusion or unusual drowsiness. This is related to the possibility of reduced drug clearance in this age group.

Q: Is Facid studied for use in children or adolescents?

A: Facid is indicated for use in pediatric patients one year of age and older for certain approved conditions. It is also conditionally indicated for infants (birth to less than one year) for GERD (reflux disease) using the oral suspension form.

Q: What is the research say about Facid's effectiveness compared to a placebo?

A: Clinical studies have been conducted using placebo-controlled trials as part of the regulatory review process. The results of these trials are a key part of the documentation used by regulatory bodies to evaluate the drug’s approved indications.

Q: Is Facid the same type of medicine as other treatments for this condition?

A: Facid belongs to the Histamine H2-receptor antagonist class. Other medicines used for similar conditions, such as Proton Pump Inhibitors ( PPIs), belong to different pharmacological classes and affect the acid-production pathway in distinct ways.

Q: Are there any long-term health concerns associated with using Facid?

A: Safety data across clinical trials, including an extension study where participants were monitored for up to two years, was assessed by regulators. This comprehensive data was used to establish the overall safety profile and adverse event information for long-term use of the drug.

Q: How quickly does Facid start working after taking it?

A: Official product information, based on clinical pharmacology data, describes the drug's onset of action. Following oral administration, the effect is generally observed to begin within one hour.

Q: Is Facid supposed to be taken at a specific time of day?

A: The timing of administration is often related to the specific condition being treated. For certain conditions, such as the treatment of acute ulcers, the drug is often administered once daily at bedtime, or sometimes twice daily. The oral tablets and suspension can generally be taken with or without food.

Q: Does Facid affect sleep or cause drowsiness?

A: Official safety documents list insomnia (trouble sleeping) as a rare psychic disturbance, and somnolence (drowsiness) as a very rare nervous system disorder. These are documented possibilities, though not commonly reported.

Q: Are there any food restrictions or specific dietary advice for Facid?

A: The oral medicine itself can generally be taken with or without food. However, official advice for non-prescription use includes suggestions to limit or avoid foods and beverages that are known to trigger acid-related symptoms. This advisory often mentions items such as caffeine, chocolate, fatty foods, spicy foods, and alcohol.

Q: What is the status of ongoing research into new uses for Facid?

A: Research into the active compound continues, and it is currently being investigated in registered clinical trials for various conditions outside of its initial approvals. This includes studies for new uses, such as in some Post-COVID-19 related conditions, as documented on authoritative trial registries.

Q: How long does Facid stay active in the body?

A: Pharmacokinetic data indicates that the effect of the drug in reducing acid secretion generally lasts for approximately 10 to 12 hours. The elimination half-life, which describes how long it takes for half of the drug to be cleared from the system, is typically between 2.5 to 3.5 hours.

Q: Can Facid be taken with coffee or caffeine?

A: Clinical data indicates the drug can inhibit gastric secretions stimulated by caffeine. Despite this, Official advice for non-prescription use includes a suggestion to limit caffeine intake. This is due to the fact that caffeine is a substance that may stimulate acid production and trigger the symptoms the medicine is intended to treat.

Q: Is Facid a generic drug or still under patent?

A: Facid is the active ingredient ( Famotidine) and is available both as a brand-name product and as generic versions approved by regulatory bodies. The FDA has confirmed that the original brand-name product was not withdrawn for safety or effectiveness reasons, allowing for generic applications.

Q: Does Facid have any known impact on fertility?

A: Official labeling documents that the drug is excreted into human milk. Regulatory status for use during pregnancy is conditional, meaning it is considered only if clearly needed. Specific information regarding the drug's impact on fertility is generally not a core component of regulatory labeling unless it is determined to be clinically significant to the approved use.

Q: What kind of special handling or storage is required for Facid?

A: The regulatory requirements for the tablet form specify storage at Controlled Room Temperature and protection from moisture. Specialized preparations, such as the intravenous solution used in acute care settings, have additional requirements for handling and storage due to their unique formulation and intended use.

Q: Why are people with specific heart conditions advised against using Facid?

A: Although rare, the medication has been associated with certain cardiac effects, including heart rhythm changes, such as a fast, irregular, pounding, or racing heartbeat. Because of this potential risk, regulatory information highlights the need for patients with a history of heart rhythm problems to be clearly identified.

Q: Does Facid cause dry mouth or changes in taste?

A: Official safety documents list dry mouth as an uncommon side effect. Taste disorders (such as a bad, unusual, or unpleasant taste) have also been documented, though they are classified as rare side effects.

How should Facid be stored and disposed of?

Storage Conditions

Facid (famotidine) tablets must be stored at Controlled Room Temperature, officially maintained between 20 C to 25 C (68 F to 77 F). The regulatory labeling permits brief excursions between 15 C and 30 C. To maintain stability and product integrity, the medicine must be actively protected from moisture, heat, and direct light, and stored in a tightly closed container.

Child-Safety Storage

It is a mandatory regulatory requirement that Famotidine tablets are stored in a location that is kept out of reach of children at all times.

Official Disposal Instructions

The preferred method for discarding unused or expired tablets is through an authorized drug take-back program. If this is unavailable, the medicine should be mixed with an unappealing substance, placed in a sealed container, and then discarded in the household trash, following official governmental guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Facid found in:

A-Z Index: